SLC5A2 and type 2 diabetes mellitus: Despite advances in DM treatment, particularly with the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists for type 2 diabetes (T2D), glucose-centered therapies moderately reduce cardiovascular risk while at the same time increasing the risk for hypoglycemia3.